864825-81-0

Basic information

• Product Name: 4-BROMO-3,5-DIMETHYL-BENZAMIDE
• Synonyms: 4-Bromo-3,5-dimethylbenzamide;BenzaMide, 4-broMo-3,5-diMethyl-
• CAS NO: 864825-81-0
• Molecular Formula: C₉H₁₀BrNO
• Molecular Weight: 228.09
• Mol File: 864825-81-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 261.1 °C at 760 mmHg
• Flash Point: 111.7 °C
• Appearance: /
• Density: 1.454 g/cm³
• Vapor Pressure: 0.0118mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-BROMO-3,5-DIMETHYL-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3,5-DIMETHYL-BENZAMIDE(864825-81-0)
• EPA Substance Registry System: 4-BROMO-3,5-DIMETHYL-BENZAMIDE(864825-81-0)

Safety Data

• Hazardous Substances Data: 864825-81-0(Hazardous Substances Data)

Usage

Uses

4-Bromo-3,5-dimethylbenzamide was one of the intermediates produced in preparation of imidazole derivatives as opioid receptor modulators.

InChI:InChI=1/C9H10BrNO/c1-5-3-7(9(11)12)4-6(2)8(5)10/h3-4H,1-2H3,(H2,11,12)

Upstream product

• 201230-82-2 carbon monoxide 
• 7697-32-7 4-bromo-3,5-dimethylbenzoic acid 
• 75344-77-3 4-bromo-3,5-dimethyl benzonitrile 
• 864825-79-6 4-bromo-3,5-dimethylphenyl trifluoromethanesulfonate 
• 999-97-3 1,1,1,3,3,3-hexamethyl-disilazane 
• 1379327-07-7 C₉H₈BrClO 

Downstream Products

• 75344-77-3 4-bromo-3,5-dimethyl benzonitrile 
• 864825-84-3 (Z)-2-tert-Butoxycarbonylamino-3-(4-carbamoyl-2,6-dimethyl-phenyl)acrylic acid methyl ester 
• 1458652-89-5 2-(4-bromo-3,5-dimethylphenyl)oxazole 

Relevant articles and documents

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS

The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may